Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2000
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Primary revenue drivers include EPOGEN (Epoetin alfa) and NEUPOGEN (Filgrastim).
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2000 |
Six Months Ended June 30, 2000 |
|---|---|---|
| Total Revenues | $914.4 | $1,728.5 |
| Net Income | $302.6 | $568.8 |
| Earnings Per Share (Diluted) | $0.28 | $0.52 |
| Operating Cash Flow | N/A | $656.3 |
| Cash & Marketable Securities | $1,621.1 | $1,621.1 |
| Long-Term Debt | $223.0 | $223.0 |
| Commercial Paper Outstanding | $99.7 | $99.7 |
Margins (Six Months Ended June 30, 2000):
- Operating Margin: 43.5% ($752.4M / $1,728.5M)
- Net Profit Margin: 32.9% ($568.8M / $1,728.5M)
- Cost of Sales as % of Product Sales: 12.5%
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 11.4% year-over-year for the three months ended June 30, 2000 ($914.4M vs. $820.5M) and 10.4% for the six-month period ($1,728.5M vs. $1,566.0M).
- Product Sales: EPOGEN sales rose 15% (quarterly) and 13% (six-month) driven by higher demand. NEUPOGEN sales increased 2% quarterly but decreased 5% for the six-month period due to foreign exchange effects, wholesaler inventory drawdowns, and softened demand.
- Corporate Partner Revenues: Increased 25% quarterly and 78% for the six-month period, primarily due to earnings from Kirin-Amgen related to the NESP development program.
- Expenses: Selling, general, and administrative (SG&A) expenses increased 30% quarterly and 29% for the six-month period due to higher staff costs and marketing expenses. Research and development (R&D) expenses increased 4% and 3%, respectively.
- Interest Income: Interest and other income increased 76% quarterly and 85% for the six-month period, largely due to gains on the sale of equity securities.
- Tax Rate: Effective tax rate increased to 31.2% (quarterly) and 31.0% (six-month) from 30.0% and 29.3% in the prior year, due to higher pretax income without corresponding increases in tax benefits.
Guidance, Outlook, and Risks
Outlook and Guidance:
- EPOGEN: Expected sales growth rate for 2000 is in the low teens. Growth may slow as average hematocrits rise.
- NEUPOGEN: Expected 2000 sales to be approximately flat compared to 1999, assuming current foreign exchange rates.
- Earnings Per Share: Excluding a $78 million legal award benefit to be recorded in Q3 2000, Amgen expects 2000 diluted EPS to be in the range of $1.06 to $1.08.
- Capital Expenditures: Anticipated spending of $450 million to $550 million in 2000 for global operations expansion.
Risks and Contingencies:
- Johnson & Johnson Arbitration: A settlement agreement reached in July 2000 provides Amgen with $78 million for arbitration costs (to be recognized in Q3 2000) and requires Amgen to pay $10 million regarding a 1991-1994 spillover dispute. A separate demand to terminate the license agreement remains pending with a trial set for February 2001.
- Reimbursement Risks: Potential Medicare reimbursement cuts proposed in the FY 2001 budget could impact EPOGEN and NEUPOGEN sales.
- Patent Litigation: Ongoing trial with Transkaryotic Therapies and Aventis S.A. regarding patent infringement; while some patents were removed, others remain in dispute.
Investor Verification Checklist
- Verify the timing and accounting treatment of the $78 million legal award from Johnson & Johnson, scheduled for Q3 2000 recognition.
- Monitor the outcome of the pending arbitration demand to terminate the Johnson & Johnson license agreement, with a trial date set for February 2001.
- Assess the impact of proposed FY 2001 Medicare reimbursement cuts on EPOGEN and NEUPOGEN sales volumes and pricing.
- Review the trend in NEUPOGEN demand and wholesaler inventory levels, which have recently softened.
- Confirm the status of the Transkaryotic Therapies and Aventis S.A. patent litigation regarding the '080 and '933 patents.